Focused On-demand Library for Methionine aminopeptidase 1D, mitochondrial

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.

Our library is unique due to several crucial aspects:

Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

Q6UB28

UPID:

MAP12_HUMAN

Alternative names:

Methionyl aminopeptidase type 1D, mitochondrial; Peptidase M 1D

Alternative UPACC:

Q6UB28; Q1WNX3

Background:

Methionine aminopeptidase 1D, mitochondrial, also known as Methionyl aminopeptidase type 1D or Peptidase M 1D, plays a crucial role in protein synthesis. It is responsible for removing the N-terminal methionine from nascent proteins, a process essential for protein maturation and function. This enzymatic activity is particularly important when the second residue in the protein sequence is small and uncharged.

Therapeutic significance:

Understanding the role of Methionine aminopeptidase 1D could open doors to potential therapeutic strategies. Its involvement in the initial steps of protein synthesis makes it a potential target for developing treatments aimed at diseases related to protein misfolding or malfunction, including its speculated role in colon tumorigenesis.